Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
Why 2025 is a Dynamic and Transformative Year for Collegium
09:06am, Friday, 21'st Nov 2025
COLL's bold buybacks, board refresh and expanding ADHD push highlight a year of strategic moves and rising momentum.
Bank of New York Mellon Corp Grows Stake in Collegium Pharmaceutical, Inc. $COLL
04:28am, Friday, 21'st Nov 2025
Bank of New York Mellon Corp increased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 3.1% during the second quarter, according to the company in its most recent disclosure with the
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
10:41am, Tuesday, 18'th Nov 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Collegium to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 12'th Nov 2025
STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Jefferies
Collegium Pharmaceutical: Another Solid Quarter
04:27pm, Monday, 10'th Nov 2025
Collegium Pharmaceutical, Inc. just delivered standout Q3 results, with EPS and revenue significantly surpassing expectations, driving a 15% stock surge. COLL focuses on pain management treatments and
Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript
10:06pm, Thursday, 06'th Nov 2025
Collegium Pharmaceutical, Inc. ( COLL ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Ian Karp Vikram Karnani - CEO, President, Executive VP & Director Scott Dreyer - Executi
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
10:31am, Thursday, 06'th Nov 2025
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates
09:50am, Thursday, 06'th Nov 2025
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.88 per share. This compares to earnings of $1.61 per share a year ago.
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
07:30am, Thursday, 06'th Nov 2025
– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Y
Knight Therapeutics Announces Launch of JORNAY PM™ in Canada
05:15pm, Thursday, 30'th Oct 2025
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methyl
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
11:06am, Thursday, 30'th Oct 2025
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025
08:00am, Thursday, 23'rd Oct 2025
STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on
STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have poster presentations highlighting real-world data from its differentiated
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
08:00am, Monday, 13'th Oct 2025
STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30
Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI
08:21pm, Thursday, 25'th Sep 2025
Two medical sector stocks are standing out among the recent additions to the Zacks Rank #1 (Strong Buy) list in Collegium Pharmaceutical (COLL) and Masimo Corporation (MASI).
